Exelon helps Alzheimer's disease patients to maintain greater independence

April 03, 2003 01:30 ET | Source: Novartis Pharma AG Novartis Pharma AG

Exelon® helps Alzheimer's disease patients to maintain greater independence

New findings suggest Exelon® significantly reduces decline in performance of activities of daily living in moderate to moderately severe Alzheimer's disease

Basel, 3 April 2003 - Therapy with Exelon (rivastigmine) helps patients with moderate to moderately severe Alzheimer's disease (AD) to maintain greater independence, according to an analysis of nearly 1500 patients.

Please find press release under the following link

Attachments

Media Release...

Recommended Reading

September 18, 2026 10:51 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based...
Read More
September 08, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Read More